Literature DB >> 25136105

Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.

Jan Felix Drexler1, Gilda Grard2, Alexander N Lukashev3, Liubov I Kozlovskaya3, Sindy Böttcher4, Gökhan Uslu5, Johan Reimerink5, Anatoly P Gmyl6, Raphaël Taty-Taty7, Sonia Etenna Lekana-Douki2, Dieudonné Nkoghe2, Anna M Eis-Hübinger1, Sabine Diedrich4, Marion Koopmans5, Eric M Leroy8, Christian Drosten9.   

Abstract

In 2010, a large outbreak of poliomyelitis with unusual 47% lethality occurred in Pointe Noire, Republic of Congo. Vaccine-mediated immunity against the outbreak virus was never investigated. A wild poliovirus 1 (WPV1) isolated from a fatal case (termed PV1-RC2010) showed a previously unknown combination of amino acid exchanges in critical antigenic site 2 (AgS2, VP1 capsid protein positions 221SAAL → 221PADL). These exchanges were also detected in an additional 11 WPV1 strains from fatal cases. PV1-RC2010 escaped neutralization by three different mAbs relevant for AgS2. Virus neutralization was tested in sera from fatal cases, who died before supplementary immunization (n = 24), Gabonese recipients of recent oral polio vaccination (n = 12), routinely vaccinated German medical students (n = 34), and German outpatients tested for antipoliovirus immunity (n = 17) on Vero, human rhabdomyosarcoma, and human epidermoid carcinoma 2 cells. Fatal poliomyelitis cases gave laboratory evidence of previous trivalent vaccination. Neutralizing antibody titers against PV1-RC2010 were significantly lower than those against the vaccine strain Sabin-1, two genetically distinct WPV1s isolated in 1965 and 2010 and two genetically distinct vaccine-derived PV strains. Of German vaccinees tested according to World Health Organization protocols, 15-29% were unprotected according to their neutralization titers (<1:8 serum dilution), even though all were protected against Sabin-1. Phylogenetic analysis of the WPV1 outbreak strains suggested a recent introduction of virus progenitors from Asia with formation of separate Angolan and Congolese lineages. Only the latter carried both critical AgS2 mutations. Antigenetically variant PVs may become relevant during the final phase of poliomyelitis eradication in populations with predominantly vaccine-derived immunity. Sustained vaccination coverage and clinical and environmental surveillance will be necessary.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25136105      PMCID: PMC4156724          DOI: 10.1073/pnas.1323502111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  An outbreak of poliomyelitis in Canadian Eskimos in wintertime.

Authors:  A F W PEART; A J RHODES
Journal:  Can J Public Health       Date:  1949-10

Review 2.  Antigenic structure of picornaviruses.

Authors:  P D Minor
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

3.  Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.

Authors:  M M Herremans; J H Reimerink; A Ras; H G Van Der Avoort; T G Kimman; A M Van Loon; M A Conyn-Van Spaendonck; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

4.  Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak.

Authors:  A Huovilainen; L Kinnunen; M Ferguson; T Hovi
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

5.  Three-dimensional structure of poliovirus serotype 1 neutralizing determinants.

Authors:  G S Page; A G Mosser; J M Hogle; D J Filman; R R Rueckert; M Chow
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

6.  Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination.

Authors:  D R Prevots; M L Ciofi degli Atti; A Sallabanda; E Diamante; R B Aylward; E Kakariqqi; L Fiore; A Ylli; H van der Avoort; R W Sutter; A E Tozzi; P Panei; N Schinaia; D Genovese; G Oblapenko; D Greco; S G Wassilak
Journal:  Clin Infect Dis       Date:  1998-02       Impact factor: 9.079

7.  Repertoire of antibodies against type 1 poliovirus in human sera.

Authors:  Gennady Rezapkin; Alexander Neverov; Elena Cherkasova; Emmanuel Vidor; Andrei Sarafanov; Diana Kouiavskaia; Eugenia Dragunsky; Konstantin Chumakov
Journal:  J Virol Methods       Date:  2010-08-04       Impact factor: 2.014

Review 8.  Future of polio vaccines.

Authors:  Ellie Ehrenfeld; John Modlin; Konstantin Chumakov
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

Review 9.  From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Authors:  Neal Nathanson; Olen M Kew
Journal:  Am J Epidemiol       Date:  2010-10-26       Impact factor: 4.897

10.  Transitory appearance of type 2 neutralizing antibody in patients infected with type 1 poliomyelitis virus.

Authors:  A B SABIN
Journal:  J Exp Med       Date:  1952-07       Impact factor: 14.307

View more
  11 in total

Review 1.  Models to predict the public health impact of vaccine resistance: A systematic review.

Authors:  Molly C Reid; Kathryn Peebles; Sarah E Stansfield; Steven M Goodreau; Neil Abernethy; Geoffrey S Gottlieb; John E Mittler; Joshua T Herbeck
Journal:  Vaccine       Date:  2019-07-12       Impact factor: 3.641

2.  Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).

Authors:  Lise Schotte; Bert Thys; Mike Strauss; David J Filman; Bart Rombaut; James M Hogle
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

3.  Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis.

Authors:  Thomas Briese; Amit Kapoor; Nischay Mishra; Komal Jain; Arvind Kumar; Omar J Jabado; W Ian Lipkin
Journal:  MBio       Date:  2015-09-22       Impact factor: 7.867

4.  Strain-dependent neutralization reveals antigenic variation of human parechovirus 3.

Authors:  Eveliina Karelehto; Sabine van der Sanden; James A Geraets; Aušra Domanska; Lonneke van der Linden; Dionne Hoogendoorn; Gerrit Koen; Hetty van Eijk; Shabih Shakeel; Tim Beaumont; Menno de Jong; Dasja Pajkrt; Sarah J Butcher; Katja C Wolthers
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

Review 5.  Why does drug resistance readily evolve but vaccine resistance does not?

Authors:  David A Kennedy; Andrew F Read
Journal:  Proc Biol Sci       Date:  2017-03-29       Impact factor: 5.349

6.  Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants.

Authors:  Shelina Moonsamy; Melinda Suchard; Shabir A Madhi
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

Review 7.  Defining the Enterovirus Diversity Landscape of a Fecal Sample: A Methodological Challenge?

Authors:  Temitope Oluwasegun Cephas Faleye; Moses Olubusuyi Adewumi; Johnson Adekunle Adeniji
Journal:  Viruses       Date:  2016-01-12       Impact factor: 5.048

Review 8.  Re-Emerging Vaccine-Preventable Diseases in War-Affected Peoples of the Eastern Mediterranean Region-An Update.

Authors:  Rasha Raslan; Skye El Sayegh; Sana Chams; Nour Chams; Angelo Leone; Inaya Hajj Hussein
Journal:  Front Public Health       Date:  2017-10-25

9.  How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.

Authors:  Michael B Doud; Juhye M Lee; Jesse D Bloom
Journal:  Nat Commun       Date:  2018-04-11       Impact factor: 14.919

10.  Deconvolving mutational patterns of poliovirus outbreaks reveals its intrinsic fitness landscape.

Authors:  Ahmed A Quadeer; John P Barton; Arup K Chakraborty; Matthew R McKay
Journal:  Nat Commun       Date:  2020-01-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.